How Sirtuin Levels Change During Behçet Disease (NCT06266247) | Clinical Trial Compass
UnknownNot Applicable
How Sirtuin Levels Change During Behçet Disease
Turkey (Türkiye)60 participantsStarted 2024-01-15
Plain-language summary
Our primary aim in our study is to evaluate the relationship between the activity, which will be evaluated by clinical and standard phase reactants, and the IL-6 and TNF-α levels, which will be measured in serum, in Behçet\'s patients. Our secondary aim was to evaluate Sirtuin-1 in Behcet\'s patients and compare it with the normal population. Our third aim is to find out whether there is a relationship between these values and organ involvement.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
• Patients diagnosed with Behçet's disease between the ages of 18-65 who come to the Rheumatology Polyclinic for their normal routine check-up.
Exclusion Criteria:
* Suffer from other arthritis or joint diseases;
* Combined with severe liver and kidney function damage or metabolic diseases (such as thyroid and parathyroid diseases), affecting bone metabolism;
* Combined with serious cardiovascular and cerebrovascular diseases or chronic kidney diseases;
* Combined with tumour and bone metastasis;
* Taking anticancer drugs or other drugs that affect bone metabolism;
* Pregnant or lactating women;
* Exclude other autoimmune disease
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is measuring sirtuin levels, IL-6, and TNF-α in people with Behçet's disease — could my own inflammation markers be tested as part of my regular care to give us a similar picture of my disease activity?
2Since this trial is listed as an observational study with an unknown recruitment status, is it still actively enrolling patients, and would it even be worth pursuing at this point?
3This study focuses on understanding the biology of Behçet's disease rather than testing a new treatment — given that, how would participating actually affect my day-to-day care or the treatment decisions we make together?
4Because Behçet's disease involves vasculitis and systemic inflammation, would joining a study that requires blood draws and monitoring create any additional risks or burdens given my current symptom level?
5Are there any treatment-focused trials for Behçet's disease — perhaps targeting IL-6 or TNF-α directly — that might be a more appropriate next step for me compared to this observational study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Our primary aim is to evaluate the relationship between the activity to be evaluated with clinical and standard acute phase reactants and the IL-6 and TNF-α levels to be measured in serum in Behçet's patients.
Timeframe: From enrollment to the end of treatment at 6 months"